For instance, in a recent prospective and randomized phase III clinical trial, Pasquine et al. [13] have demonstrated that complete elimination of immune cells by enrichment of the CD34+ cells lowers long-term morbidity as a result of a substantially reduced chronic GVHD, without negatively impacting relapse rates in patients with acute myeloid leukemia (AML). Here, CD34 is linked to acute myeloid leukemia.